Asset Details
Do you wish to reserve the book?
The host STING pathway at the interface of cancer and immunity
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
The host STING pathway at the interface of cancer and immunity
Do you wish to request the book?
The host STING pathway at the interface of cancer and immunity
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
The host STING pathway at the interface of cancer and immunity
2016
Overview
A major subset of human cancers shows evidence for spontaneous adaptive immunity, which is reflected by the presence of infiltrating CD8+ T cells specific for tumor antigens within the tumor microenvironment. This observation has raised the question of which innate immune sensing pathway might detect the presence of cancer and lead to a natural adaptive antitumor immune response in the absence of exogenous infectious pathogens. Evidence for a critical functional role for type I IFNs led to interrogation of candidate innate immune sensing pathways that might be triggered by tumor presence and induce type I IFN production. Such analyses have revealed a major role for the stimulator of IFN genes pathway (STING pathway), which senses cytosolic tumor-derived DNA within the cytosol of tumor-infiltrating DCs. Activation of this pathway is correlated with IFN-β production and induction of antitumor T cells. Based on the biology of this natural immune response, pharmacologic agonists of the STING pathway are being developed to augment and optimize STING activation as a cancer therapy. Intratumoral administration of STING agonists results in remarkable therapeutic activity in mouse models, and STING agonists are being carried forward into phase I clinical testing.
Publisher
American Society for Clinical Investigation
Subject
/ Analysis
/ Animals
/ Antigen-Presenting Cells - immunology
/ Antigens
/ Antineoplastic Agents - pharmacology
/ Cancer
/ CD8-Positive T-Lymphocytes - cytology
/ Dendritic Cells - immunology
/ DNA
/ Humans
/ Interferon-beta - immunology
/ Ligands
/ Melanoma
/ Mice
/ Review
/ T cells
/ Tumor Microenvironment - immunology
/ Tumors
